Explore our materials

Filters

Results (5576)

Slideset

HIV

European HIV Clinical Forum 2016

Switching from combination antiretroviral therapy (cART) to dolutegravir (DTG) monotherapy in virologically suppressed HIV-1 infected adults: a randomized multicenter, non-inferiority clinical trial (DOMONO) - Ingeborg Wijting

Slideset

HIV

European HIV Clinical Forum 2016

Lamivudine plus either Atazanavir/ritonavir, Darunavir/ritonavir or Dolutegravir as switch strategies in HIV-positive, virologically-suppressed patients: a comparison - Alberto Borghetti

Diane Descamps

MD, PHD

Slideset

HIV

European HIV Clinical Forum 2016

Virological response of HIV-infected-patients virologically-suppressed switching to a DTG-based regimen in an observational cohort based on the genotypic susceptibility score - Diane Descamps

Saye Khoo

MD, PhD

Slideset

HIV

European HIV Clinical Forum 2016

Clinical Utility of Integrase Inhibitors during pregnancy - Saye Khoo, MD, PhD

AMG

Anna Maria Geretti

MD, PhD, FRCPath

Slideset

HIV

European HIV Clinical Forum 2016

Clinical Case Presentations – How to manage drug - drug interactions - the practice - Anna Maria Geretti, MD, PhD, FRCPath

Slideset

HIV

European HIV Clinical Forum 2016

An Italian case of transmitted integrase inhibitor resistance in a drug-naïve patient: a refined analysis by ultra-deep-454 pyrosequencing - Ada Bertoli

Slideset

HIV

European HIV Clinical Forum 2016

French National survey of resistance to integrase inhibitors shows high differences of resistance selection rate in case of virological failure in a context of routine hospital care (ANRS AC11 virology network) - Vincent Calvez

Slideset

HIV

European HIV Clinical Forum 2016

Virological failure even at low levels of viremia can be associated to integrase strand-transfer inhibitors resistance in HIV-1 infected patients - Benet Garrabé

CVF

Courtney V. Fletcher

PharmD

Slideset

HIV

European HIV Clinical Forum 2016

Impact on: Pharmacology – penetration to sanctuary sites and drug-drug interactions - Courtney Fletcher, PharmD

Slideset

HIV

European HIV Clinical Forum 2016

A Multicenter Observational Study on the Efficacy and Tolerability of Dolutegravir combined with Tenofovir/Emtricitabine or Abacavir/Lamivudine as a Switch Strategy for HIV-1 Pos. ART-exp. Patients with Stable Viral Suppression- Alberto Borghetti

Daniel Kuritzkes

Slideset

HIV

European HIV Clinical Forum 2016

Impact on: Virology/Resistance - Daniel Kuritzkes, MD

Slideset

HIV

European HIV Clinical Forum 2016

Explore our materials

Your Selection Clear All

Topic

Material Type

Event

Switching from combination antiretroviral therapy (cART) to dolutegravir (DTG) monotherapy in virologically suppressed HIV-1 infected adults: a randomized multicenter, non-inferiority clinical trial (DOMONO) - Ingeborg Wijting

Lamivudine plus either Atazanavir/ritonavir, Darunavir/ritonavir or Dolutegravir as switch strategies in HIV-positive, virologically-suppressed patients: a comparison - Alberto Borghetti

Virological response of HIV-infected-patients virologically-suppressed switching to a DTG-based regimen in an observational cohort based on the genotypic susceptibility score - Diane Descamps

Clinical Utility of Integrase Inhibitors during pregnancy - Saye Khoo, MD, PhD

Clinical Case Presentations – How to manage drug - drug interactions - the practice - Anna Maria Geretti, MD, PhD, FRCPath

An Italian case of transmitted integrase inhibitor resistance in a drug-naïve patient: a refined analysis by ultra-deep-454 pyrosequencing - Ada Bertoli

French National survey of resistance to integrase inhibitors shows high differences of resistance selection rate in case of virological failure in a context of routine hospital care (ANRS AC11 virology network) - Vincent Calvez

Virological failure even at low levels of viremia can be associated to integrase strand-transfer inhibitors resistance in HIV-1 infected patients - Benet Garrabé

Impact on: Pharmacology – penetration to sanctuary sites and drug-drug interactions - Courtney Fletcher, PharmD

A Multicenter Observational Study on the Efficacy and Tolerability of Dolutegravir combined with Tenofovir/Emtricitabine or Abacavir/Lamivudine as a Switch Strategy for HIV-1 Pos. ART-exp. Patients with Stable Viral Suppression- Alberto Borghetti

Impact on: Virology/Resistance - Daniel Kuritzkes, MD

Impact on: Adherence/tolerability - Ian McGowan, MB, ChB, DPhil, MD, FRCP